Candriam SCA’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-345,384
| Closed | -$20.1M | – | 692 |
|
|
2024
Q3 | $20.1M | Sell |
345,384
-96,471
| -22% | -$5.6M | 0.12% | 178 |
|
|
2024
Q2 | $20.2M | Sell |
441,855
-210,144
| -32% | -$9.6M | 0.12% | 167 |
|
|
2024
Q1 | $43.2M | Sell |
651,999
-167,063
| -20% | -$11.1M | 0.28% | 82 |
|
|
2023
Q4 | $32.6M | Buy |
819,062
+78,001
| +11% | +$3.1M | 0.22% | 100 |
|
|
2023
Q3 | $23.6M | Buy |
741,061
+20,000
| +3% | +$638K | 0.17% | 120 |
|
|
2023
Q2 | $29M | Sell |
721,061
-23,996
| -3% | -$964K | 0.21% | 124 |
|
|
2023
Q1 | $29.3M | Buy |
745,057
+119,143
| +19% | +$4.68M | 0.2% | 123 |
|
|
2022
Q4 | $30.1M | Buy |
625,914
+264,125
| +73% | +$12.7M | 0.2% | 117 |
|
|
2022
Q3 | $13.6M | Hold |
361,789
| – | – | 0.1% | 214 |
|
|
2022
Q2 | $10M | Sell |
361,789
-58,881
| -14% | -$1.63M | 0.08% | 225 |
|
|
2022
Q1 | $22.9M | Buy |
420,670
+179,724
| +75% | +$9.77M | 0.16% | 148 |
|
|
2021
Q4 | $14.1M | Hold |
240,946
| – | – | 0.09% | 218 |
|
|
2021
Q3 | $9.53M | Buy |
240,946
+139,537
| +138% | +$5.52M | 0.06% | 282 |
|
|
2021
Q2 | $4.31M | Buy |
+101,409
| New | +$4.31M | 0.03% | 437 |
|